Department of Otolaryngology, Head and Neck Surgery, Rhinology Unit, Virgen Macarena University Hospital, Doctor Fedriani Av. 3, Seville, 41009, Spain.
Unidad de Rinología y Asma, UGC ORL, Hospital Universitaro De Jerez, Instituto De Investigación Biomedica De Cadiz (INIBICA), Jerez, 11407, Spain.
Curr Allergy Asthma Rep. 2023 Dec;23(12):733-746. doi: 10.1007/s11882-023-01113-x. Epub 2023 Nov 22.
The advances in the knowledge of the molecular basis of the inflammatory response in chronic rhinosinusitis with nasal polyps (CRSwNP) have led the management of these patients towards personalized and precision medicine. Surgery has been positioned as a suitable alternative in patients who do not achieve control with appropriate medical treatment, but polypoid recurrences remain a constraint. The emergence of new surgical approaches based on patient phenotyping and the poor disease control associated with type 2 inflammatory phenotype makes it necessary to review the role of personalized and precision surgery in managing the disease.
Surgical approaches based on wide resection of bony sinus structures and the treatment of mucosa lining the sinonasal cavity have been analyzed and compared with other techniques and seem to offer more favorable surgical outcomes and improved quality of life (QoL), in addition to lower relapse rates. The innovations with new complementary surgical techniques, such as reboot surgery adding an extended autologous mucosal graft from the nasal floor (mucoplasty), may benefit endoscopic and QoL outcomes in the most severe CRSwNP patients with type 2 phenotype. Using bilateral endonasal mucoplasty as a complementary technique to reboot surgery is a suitable technical choice that has improved short- and medium-term QoL and endoscopic outcomes for patients with severe CRSwNP. These results are likely due to a combination of the extension of reboot and the inherent inflammatory and healing properties of mucoplasty. We propose this technique as a valuable surgical resource, although more robust clinical studies are needed to evaluate its long-term benefits comprehensively.
慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)炎症反应分子基础的研究进展使这些患者的治疗转向了个性化和精准医学。对于那些经适当药物治疗未能控制的患者,手术已被定位为一种合适的替代方法,但息肉样复发仍然是一个限制。基于患者表型的新手术方法的出现以及与 2 型炎症表型相关的疾病控制不佳,使得有必要重新评估个性化和精准手术在疾病管理中的作用。
基于广泛切除骨窦结构和治疗鼻腔鼻窦腔衬里黏膜的手术方法已经进行了分析,并与其他技术进行了比较,除了复发率较低外,这些方法似乎提供了更有利的手术结果和改善的生活质量(QoL)。采用新的补充性手术技术的创新,如重新启动手术中增加来自鼻底的扩展自体黏膜移植物(黏膜成形术),可能有益于 2 型表型最严重的 CRSwNP 患者的内镜和 QoL 结果。作为重新启动手术的补充技术,双侧经鼻黏膜成形术是一种合适的技术选择,可改善严重 CRSwNP 患者的短期和中期 QoL 和内镜结果。这些结果可能是由于重新启动的扩展和黏膜成形术固有的炎症和愈合特性的结合。尽管需要更强大的临床研究来全面评估其长期益处,但我们仍建议将该技术作为一种有价值的手术资源。